DBV Technologies S.A. (NASDAQ:DBVT) Weekly Ratings on Jun 27, 2018

June 27, 2018 - By Anthony Rauscher

DBV Technologies S.A. (NASDAQ:DBVT) Corporate Logo

DBV Technologies S.A. (NASDAQ:DBVT) Ratings Coverage

In total 3 analysts cover DBV Technologies SA – American (NASDAQ:DBVT). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:DBVT) has 100% bullish analysts. 3 are the (NASDAQ:DBVT)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Thursday, March 15 the rating was maintained by H.C. Wainwright with “Buy”. In Tuesday, March 27 report Deutsche Bank maintained the stock with “Buy” rating. Listed here are DBV Technologies S.A. (NASDAQ:DBVT) PTs and latest ratings.

27/03/2018 Broker: Deutsche Bank Rating: Buy New Target: $33.0000 Maintain
15/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $50.0 Maintain
14/02/2018 Broker: Citigroup Rating: Buy New Target: $57.0

The stock decreased 0.71% or $0.14 during the last trading session, reaching $19.53.Currently DBV Technologies S.A. is downtrending after 29.21% change in last June 27, 2017. DBVT has also 37,198 shares volume. The stock underperformed the S&P 500 by 41.78%.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.The company has $1.16 billion market cap. The Company’s lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.Last it reported negative earnings. The firm is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cowÂ’s milk protein allergy and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of henÂ’s egg allergy; and booster vaccine for Bordatella pertussis.

More recent DBV Technologies S.A. (NASDAQ:DBVT) news were published by Nasdaq.com, Seekingalpha.com and Nasdaq.com. The first one has “DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 – Procedures for Obtaining …” as a title and was published on June 01, 2018. The next is “Aimmune Therapeutics: Special Situation Biotech Opportunity” on June 08, 2018. And last was published on June 04, 2018, called “Investor Expectations to Drive Momentum within Momo, Barrick Gold, Grupo Financiero Santander Mexico SAB de CV …”.

DBV Technologies S.A. (NASDAQ:DBVT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.